Ramnik Xavier Increases Stake in MoonLake Immunotherapeutics

Ramnik Xavier has increased his stake in MoonLake Immunotherapeutics by acquiring 22,195 shares. This transaction took place on June 17, 2026, with the stock trading around $19.19 on the Nasdaq Capital Market. The filing indicates an insider's belief in the company's potential.

MoonLake Immunotherapeutics Stock Snapshot

Shares of NasdaqCM:MLTX traded near $19.19 recently. MoonLake Immunotherapeutics has a market capitalization of about $1.41 billion. The company is not currently profitable, thus it has no meaningful P/E ratio. Its forward P/E is reported at -5.57, reflecting its current lack of earnings. The stock has experienced a wide 52-week range, from a low of $5.95 to a high of $62.75. It has a 50-day moving average of $17.88 and a 200-day moving average of $19.01. The company's financial health is supported by a strong current ratio of 8.60 and a quick ratio of 7.89, with a debt-to-equity ratio of 39.68.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biotechnology company based in Zug, Switzerland. It focuses on developing treatments for inflammatory skin and joint diseases. The company is working on Sonelokimab, a tri-specific IL-17A and IL-17F inhibiting Nanobody, aimed at treating conditions such as hidradenitis suppurativa, psoriatic arthritis, and psoriasis. Founded in 2021, the company is led by CEO Dr. Jorge Santos da Silva and employs around 130 people.

Bottom Line

Ramnik Xavier's recent purchase of MoonLake Immunotherapeutics shares suggests confidence in the company's future. Investors often track insider transactions like this to gauge sentiment. However, it's important to remember that insider transactions are reported after the fact and may not reflect the current position. MoonLake continues to focus on its innovative therapies for inflammatory diseases, making it a company to watch in the biotechnology sector.